Roche ends KRAS deal with Hookipa Pharma, as biotech lays off 30% of staff
Roche is waving goodbye to a KRAS program it partnered on less than a year and a half ago.
The Swiss conglomerate ended its collaboration …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
